Description

Salbutamol 4 mg

Marque : Magnus Pharmaceuticals
Contenu : 100 tablets | 4 mg per tablet
Prix : €29
Fabriqué en : L'Europe

🧪 Aperçu du produit

Salbutamol 4 mg delivers a fast-acting β2-adrenergic agonist commonly used in airway research and cardiopulmonary modeling. Known in the U.S. as albuterol, this compound supports investigations into bronchodilation, exercise-induced asthma mitigation, airway-smooth-muscle signaling, and fat-loss models tied to β2 stimulation.

With onset in ~30 minutes and duration of 4–6 hours, oral salbutamol enables dynamic testing across acute and chronic studies. A 5–6 hour half-life supports twice-daily dosing in respiratory-performance trials, and its oral form simplifies lab handling over inhaler-based delivery.

✅ Principaux résultats de la recherche

Potent bronchodilation:
4 mg oral dose improves FEV₁ and FVC in mild asthma cohorts within 30 minutes [PubMed]

Respiratory-performance models:
Improved inspiratory capacity and reduced residual lung volume documented in exercise-based studies [PubMed]

Systemic β₂ activity:
Promotes intracellular potassium shift and raises heart rate — relevant for cardiometabolic modeling [Mayo Clinic]

Anti-doping relevance:
WADA bans all oral forms; only inhaled ≤1,600 µg/day permitted — tablet exposure triggers positive test [wada-ama.org]

Room-temperature stable:
Film-coated tablets retain potency at ≤25 °C for ≥36 months — better shelf life than inhaler solutions [nhs.uk]

🧬 Applications suggérées en laboratoire

Bronchodilation and airway-smooth-muscle pharmacology
Exercise-induced asthma and VO₂-max modeling
β2-agonist thermogenic & fat-loss studies
Hypokalaemia and systemic electrolyte tracking
Cardiopulmonary performance and heart-rate stress simulations

📊 Spécifications techniques

Champ d'application	Données
Nom chimique	Salbutamol (INN) / Albuterol (USAN)
Formule chimique	C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub>
Synonymes	Albuterol; (+/-)-Salbutamol; 1-(4-(tert-butylamino)-2-hydroxybenzyl)-2-(hydroxymethyl)-phenol
Poids moléculaire	239.31 g/mol
Numéro CAS	18559-94-9 (base); 51022-70-9 (sulfate)
Demi-vie	~5–6 hours (oral), onset ~30 min
Fenêtre de détection	≥24 hours (oral), varies by dose
Avantages documentés	↑ FEV₁, ↓ airway resistance, ↑ VO₂-max, thermogenic modeling
Principaux risques	Tremor, tachycardia, hypokalaemia, insomnia, bronchospasm
Composé actif total	400 mg per carton (4 mg × 100 tablets)
Durée de conservation	36 months (manufacturer specification)

❄️ Perspectives de recherche soutenues par PubChem

Promotes rapid bronchodilation in obstructive lung models
Improves peak expiratory metrics (FEV₁, FVC) in dose-dependent trials
Shown to increase cardiac output and VO₂-max in heart-failure studies
Studied for thermogenic/lipolytic effects in β2-stimulation models
Oral route supports longer systemic effect and steady sampling

⚠️ Effets secondaires documentés par la recherche

Common: Tremor, headache, insomnia, and tachycardia
Dose-related: Hypokalaemia due to potassium shift
Rare: Paradoxical bronchospasm during airway-sensitive protocols
Cardiovascular strain at elevated exposure

🧯 Manipulation et conformité

Réservé à la recherche — Not for human or veterinary use
Store at 15–25°C, protect from light and moisture
Purchase confirms qualified researcher status
Listed under WADA S3 (β2-agonists) — oral exposure prohibited without TUE